×
COVID-19 drugs chloroquine and hydroxychloroquine, but not azithromycin and remdesivir,...
https://doi.org/10.1124/jpet.120.000484
The Journal of Pharmacology and Experimental Therapeutics; Szendrey M, Guo J et. al.

Mar 6th, 2021 - Drug-induced long QT syndrome (LQTS) is an established cardiac side effect of a wide range of medications, which represents a significant concern for drug safety. The rapidly (IKr) and slowly activating delayed rectifier K+ current (IKs) mediated by channels encoded by the human ether-a-go-go-related- gene (hERG) and KCNQ1+KCNE1, respectively, are two main currents responsible for ventricular r...

In vitro activity of itraconazole against SARS-CoV-2.
https://doi.org/10.1002/jmv.26917
Journal of Medical Virology; Damme EV, De Meyer S et. al.

Mar 5th, 2021 - Although vaccination campaigns are currently being rolled out to prevent coronavirus disease (COVID-19), antivirals will remain an important adjunct to vaccination. Antivirals against coronaviruses do not exist, hence global drug repurposing efforts have been carried out to identify agents that may provide clinical benefit to patients with COVID-19. Itraconazole, an antifungal agent, has been r...

Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929896
European Journal of Clinical Pharmacology; von Hentig N

Mar 4th, 2021 - SARS-CoV-2 is a single-stranded RNA virus which is part of the ß-coronavirus family (like SARS 2002 and MERS 2012). The high prevalence of hospitalization and mortality, in addition to the lack of vaccines and therapeutics, forces scientists and clinicians around the world to evaluate new therapeutic options. One strategy is the repositioning of already known drugs, which were approved drugs fo...

Clinical profiles and outcome of patients with COVID-19 in a specialized hospital in Ja...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929897
Journal of Anesthesia; Oda Y, Shiraishi S et. al.

Mar 4th, 2021 - To characterize the clinical features and outcome of patients treated at a specialized hospital for coronavirus disease 2019 (COVID-19). We retrospectively reviewed the symptoms on admission, treatment, and outcome of a total of 300 patients with mild (peripheral oxygen saturation (SpO2) ≥ 96%), moderate I (93% < SpO2 < 96%), moderate II (SpO2 ≤ 93%) and severe (requiring admission to the ICU o...

EU, Under Pressure Over Vaccine Rollouts, Considers Switch to Emergency Approvals
https://www.medscape.com/viewarticle/946712

Mar 2nd, 2021 - BRUSSELS (Reuters) - The European Commission said on Tuesday that it was considering emergency approvals for COVID-19 vaccines as a faster alternative to more rigorous conditional marketing authorisations which have been used so far. The move would mark a big shift in approach to vaccine approvals, as it would entail using a procedure that the EU had considered dangerous and that before the COV...

Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Act...
https://doi.org/10.1021/acsinfecdis.0c00761
ACS Infectious Diseases; Hu Y, Ma C et. al.

Mar 1st, 2021 - As the COVID-19 pandemic continues to unfold, the morbidity and mortality are increasing daily. Effective treatment for SARS-CoV-2 is urgently needed. We recently discovered four SARS-CoV-2 main protease (Mpro) inhibitors including boceprevir, calpain inhibitors II and XII, and GC-376 with potent antiviral activity against infectious SARS-CoV-2 in cell culture. In this study, we further charact...

COVID-19: Potential Repurposing Drugs.
https://doi.org/10.2174/1871526521666210301143441
Infectious Disorders Drug Targets; Leowattana W

Mar 1st, 2021 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the most infectious diseases and caused coronavirus disease in 2019 (COVID-19). It has been widely spread worldwide and infected more than 28 million peoples in 215 countries, and more than 920,000 have now died from COVID-19. To date, no effective antiviral drugs or specific vaccines have been discovered yet. In this bewild...

Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910147
Clinical Microbiology and Infection : the Official Public... Touafchia A, Bagheri H et. al.

Mar 1st, 2021 - In recent clinical trials some cardiac arrhythmias were reported with use of remdesivir for COVID-19. To address this safety concern, we investigated whether use of remdesivir for COVID-19 is associated with an increased risk of bradycardia. Using VigiBase®, the World Health Organization Global Individual Case Safety Reports database, we compared the cases of bradycardia reported in COVID-19 pa...

A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908839
International Journal of Infectious Diseases : IJID : Off... Mehta RM, Bansal S et. al.

Mar 1st, 2021 - Remdesivir is the current recommended anti-viral treatment in moderate-to-severe COVID-19. However, data on impact of timing of therapy, efficacy, and safety are limited. We evaluated the impact of timing of remdesivir initiation (symptom-onset to remdesivir treatment [SORT] interval) on in-hospital all-cause mortality in patients with moderate-to-severe COVID-19. This retrospective study was c...

Practical Remdesivir Synthesis through One-Pot Organocatalyzed Asymmetric (S)-P-Phospho...
https://doi.org/10.1021/acs.joc.0c02888
The Journal of Organic Chemistry; Gannedi V, Villuri BK et. al.

Feb 26th, 2021 - Remdesivir, an inhibitor of RNA-dependent RNA polymerase developed by Gilead Sciences, has been used for the treatment of COVID-19. The synthesis of remdesivir is, however, challenging, and the overall cost is relatively high. Particularly, the stereoselective assembly of the P-chirogenic center requires recrystallization of a 1:1 isomeric p-nitrophenylphosphoramidate mixture several times to o...

Pharmacological considerations for the treatment of COVID-19 in people living with HIV ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919104
Expert Opinion on Pharmacotherapy; Gutierrez MDM, Mur I et. al.

Feb 26th, 2021 - When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. ...

A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835...
https://doi.org/10.1128/JVI.01819-20
Journal of Virology; de Vries M, Mohamed AS et. al.

Feb 24th, 2021 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of Coronavirus Disease 2019 (COVID-19). There is a dire need for novel effective antivirals to treat COVID-19, as the only approved direct-acting antiviral to date is remdesivir, targeting the viral polymerase complex. A potential alternate target in the viral life cycle is the main SARS-CoV-2 protease 3CLpro ...

EU Drug Watchdog to Weigh in on Extended Use for Remdesivir by Summer
https://www.medscape.com/viewarticle/946303

Feb 23rd, 2021 - (Reuters) - Europe's drugs regulator said on Tuesday it was expecting to give an opinion before the summer on whether Gilead Sciences' remdesivir can be used to treat COVID-19 patients who do not need oxygen support. The indication for extended use, if approved, would allow the antiviral treatment to be given to more patients as coronavirus infections surge and healthcare systems are pressured ...

FDA Approvals, Highlights, and Summaries:  Infectious Disease
https://reference.medscape.com/viewarticle/945189

Feb 23rd, 2021 - Veklury (remdesivir) Remdesivir is an antiviral agent that inhibits SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), which is essential for viral replication. It was the first drug approved by the FDA for treating the SARS-CoV-2 virus infection. It is indicated for adults and pediatric patients aged 12 years and older who weigh at least 40 kg for treatment of coronavirus disease 2019 (COVID-19) ...

Coronavirus disease 2019 management.
https://doi.org/10.1097/MCP.0000000000000766
Current Opinion in Pulmonary Medicine; Wilson KC

Feb 19th, 2021 - Coronavirus disease 2019 (COVID-19) is an acute multisystem disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Investigations are ongoing in the search for effective therapeutics, with clinical approaches evolving based upon such evidence. The antiviral agent, remdesivir, and the immunomodulator, dexamethasone, are the first therapeutics for which there is evidence ...

The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Sympto...
https://doi.org/10.1089/gtmb.2020.0227
Genetic Testing and Molecular Biomarkers; Younis NK, Zareef RO et. al.

Feb 17th, 2021 - Coronavirus disease 2019 (COVID-19) displays a broad spectrum of clinical presentations ranging from lack of symptoms to severe multiorgan system complications and death. Various laboratory assays have been employed in the diagnosis of COVID-19, including: nucleic acid-based tests; antigen tests; and serum testing for anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies....

SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discov...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888651
PLoS Pathogens; Murgolo N, Therien AG et. al.

Feb 17th, 2021 - Since the initial report of the novel Coronavirus Disease 2019 (COVID-19) emanating from Wuhan, China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally. While the effects of SARS-CoV-2 infection are not completely understood, there appears to be a wide spectrum of disease ranging from mild symptoms to severe respiratory distress, hospitalization, and mortality. T...

Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to ...
https://doi.org/10.1136/annrheumdis-2020-219725
Annals of the Rheumatic Diseases; Alunno A, Najm A et. al.

Feb 16th, 2021 - To summarise the available information on efficacy and safety of immunomodulatory agents in SARS-CoV-2 infection. As part of a European League Against Rheumatism (EULAR) taskforce, a systematic literature search was conducted from January 2019 to 11 December 2020. Two reviewers independently identified eligible studies according to the Population, Intervention, Comparator and Outcome framework ...

"Remdesivir-Associated Pancreatitis".
https://doi.org/10.1097/MJT.0000000000001266
American Journal of Therapeutics; Khadka S, Williams K et. al.

Feb 16th, 2021 - We report a case of acute pancreatitis that developed after four days of remdesivir therapy in a patient being treated for COVID-19. Despite improvement in patient's respiratory status, abdominal pain worsened and clinical signs and symptoms progressed to a diagnosis of acute pancreatitis 4 days after initiation of remdesivir therapy. Withdrawal of remdesivir paired with medical management of a...